Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Avalo Therapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $13.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 78.82% year-over-year to $13.4 million; the TTM value through Dec 2025 reached $13.4 million, up 78.82%, while the annual FY2025 figure was $13.4 million, 78.82% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $13.4 million in Q4 2025 per AVTX's latest filing, down from $14.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $14.0 million in Q3 2025 to a low of $859381.0 in Q1 2024.